<DOC>
	<DOC>NCT01508156</DOC>
	<brief_summary>The purpose of the study is to test the safety and tolerability of different doses of IDX719 to find the best dose for future studies. The study will also assess the pharmacokinetics of IDX719. No formal hypotheses will be tested.</brief_summary>
	<brief_title>Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>All Participants Is in good general health. Agrees to use doublebarrier method of birth control for at least 90 days after the last dose of study drugs. HCV Participants Has documented GT1, GT2, or GT3 chronic HCV infection. All Participants Is pregnant or breastfeeding. HCV Participants Has received prior HCV treatment. Is coinfected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>treatment-naive</keyword>
</DOC>